Adenovirus Packaging Service
Quick Turnaround Adenoviral Packaging for Research and Development
Molecular Cloning & Mutagenesis Projects Completed
Viral Vector Packaging Solutions Delivered
Plasmid DNA Preparations Successfully Produced
Let's Start Your Adenovirus Packaging Production
Adenovirus stands out as a powerful and versatile viral vector, driving innovation across cell and gene therapy, immunology, and oncology. At BioInnovatise, we specialize in transforming your plasmid DNA constructs into high quality adenoviral particles, tailored to meet your research needs with a range of flexible production options. Let us help you accelerate discovery and bring your breakthroughs closer to reality.
Below is a list of the research grade adenoviral vector services we currently provide. If you’re unsure which packaging service is right for your research, our team is more than happy to discuss your project. Our lead times often change, so be sure to check the lead time for your preferred service before you begin production.
| Purification Grade | Standard Titer | Production Volume Options |
|---|---|---|
| Crude (for in vitro) | ~10E11 IFU/ml | 250 μl; 500 μl; 1 ml |
| Ultracentrifugation purified (for in vitro or in vivo) | ~10E12 IFU/ml | 250 μl; 500 μl; 1 ml |
Our viral vector team uses a validated assay to measure the viral titer in all adenovirus productions. Viral titer is determined through RT-qPCR, utilizing primers designed to amplify conserved internal sequences in the adenoviral genome.
Adenovirus Packaging Production Additional Options
Cell lines Our lab performs adenovirus transduction using a HEK293T cell line (Human Embryonic Kidney 293 Transient) because of its high transfection efficiency to make the best use of adenovirus’ large packaging capacity. Learn more about adenovirus packaging cell line options.
Transfection protocol Viral payload, cell line, and transgene can greatly impact transfection efficiency. Because of this, we produce every adenovirus packaging to our client’s adenovirus packaging protocol specifications. If you do not have an adenovirus transfection protocol, we can determine an appropriate one based on your research needs.
Adenovirus Packaging Production Process
Quality Control
As mentioned above, all adenovirus productions have their titer levels measured with a RT-qPCR (Quantitative Reverse Transcription Polymerase Chain Reaction) assay. In addition, we can perform the following quality control tests upon request:
- A260/A280 Ratio
- Flow cytometry
- Western blot/ELISA
Adenovirus vs Lentivirus Packaging
Both adenovirus and lentivirus are highly versatile and effective vectors for delivering genetic payloads to host cells, but they have distinct characteristics that can influence their suitability for specific research applications. Understanding these differences is crucial for achieving accurate and reliable results. To explore these key distinctions, read our comprehensive guide on adenovirus vs lentivirus.
Plasmid DNA Requirements
To begin production, we require only 1 μg of your plasmid DNA. We cover all plasmid preparation expenses for your adenovirus production. Our plasmid preparations are always performed in house and result in endotoxin free and animal free plasmid DNA. To learn more, read about our plasmid preparation services.
Integrated Vector Sequencing Reports for IND Filing
Integrated Vector Sequencing Reports are a critical component of any Investigational New Drug application submitted to the FDA for gene therapy products. This analysis provides essential verification of the vector’s genetic integrity, identity, and stability. By documenting the complete nucleotide sequence of a therapeutic vector, identifying any potential sequence variants, and confirming genetic stability across manufacturing processes, this report addresses crucial regulatory requirements while demonstrating a commitment to product quality.
Our viral vector team can provide Integrated Vector Sequencing Reports for viral vectors, just ask when starting a project.
Why Choose Adenovirus As A Viral Vector
Adenovirus vectors offer several distinct advantages, making them an excellent choice for various research and therapeutic applications, particularly in vaccine development, gene therapy, and immunotherapy:
- High Transduction Efficiency: Adenovirus vectors efficiently deliver genetic material to a wide range of cell types, including dividing and non-dividing cells. This broad tropism makes them ideal for applications requiring robust gene expression across diverse tissues.
- Transient Expression: Unlike retrovirus, adenovirus does not integrate its genetic material into the host genome. This feature is advantageous for applications where transient, high-level expression is desired, such as cancer immunotherapy or vaccine delivery.
- Large Payload Capacity: Adenovirus vectors can accommodate relatively large genetic payloads (up to ~8 kb), enabling the delivery of complex genetic constructs that are too large for other vector systems like AAV.
- Strong Immunogenicity for Vaccine Development: Adenovirus’s strong ability to provoke an immune response has been successfully harnessed in vaccines like the Oxford-AstraZeneca COVID-19 vaccine. Its immunogenic properties also make it ideal for vaccines targeting infectious diseases and cancer.
- Proven Success in Oncolytic Therapeutics: Adenovirus-based oncolytic therapies are gaining traction for their ability to selectively infect and kill cancer cells while sparing normal tissue. Notable candidates include Imlygic (Talimogene laherparepvec, T-VEC), an oncolytic herpesvirus approved for melanoma, and adenovirus-based therapies like DNX-2401 (tasadenoturev) for glioblastoma and Oncorine (H101), approved in China for head and neck cancers.
Adenoviral Based Biopharmaceutical and Biotechnology Research & Development
Adenovirus is an exciting viral vector for cell and gene therapy research. Adenoviral vectors have been utilized in clinical trials and commercial applications, including vaccines for infectious diseases and oncolytic therapies for cancer. Their potential for the research and treatment of both rare and more common conditions, such as hemophilia, Duchenne muscular dystrophy, and certain cancers, continues to drive advancements in the field.
Pharmaceutical companies like AstraZeneca and Shanghai Sunway Biotech are leveraging adenoviral vectors in the development of vaccines and cancer therapies, including oncolytic adenovirus-based approaches. The Alliance for Regenerative Medicine is keeping record of current cell and gene therapy products including adenoviral based therapies available in different markets across the world.
Want to learn more about the latest in adenoviral based research? Our colleagues at ScienceDirect and Genetic Engineering & Biotechnology News are always collecting and publishing the latest information on adenovirus based research.
Trusted By Top Researchers Across Disciplines and Therapeutic Areas
Subscribe for Product Releases, New Resources, and Company Updates
13 Taft Court Suite 220
Rockville, MD 20850
(301) 838-8675
Follow Us on LinkedIn
© 2025 BioInnovatise, All Rights Reserved